, Volume 13, Issue 2, pp 231–241 | Cite as

Cost-Benefit Analysis of Risperidone and Clozapine in the Treatment of Schizophrenia in Israel

Original Research Article


In this study, the benefits and costs of treating schizophrenia with either risperidone or clozapine were examined. The lifetime drug-treatment cost incurred by a patient with schizophrenia in Israel was $US7561 (1996 values) with an initial 6-month trial with risperidone, compared with $US6326 with clozapine and $US3360 with typical antipsychotics. Total lifetime costs of psychiatric health services (excluding medications) by individuals who were continuously receiving typical antipsychotics were $US181 555 per patient.

Assuming a 6.3% decrease in hospital use with typical antipsychotics and an absolute 30% decrease with risperidone or clozapine, the use of clozapine or risperidone reduced hospitalisation costs by $US7159 per patient, but increased community-care costs by $US1627 per patient, giving health-service benefit : cost ratios of 1.87 : 1 and 1.32 : 1, respectively. After adding indirect benefits resulting from increased work productivity (minus indirect costs related to increases in transport costs because of visits for blood monitoring during clozapine therapy), the benefit : cost ratios increased to 2.04 : 1 and 1.48 : 1, respectively.

Assuming that clozapine caused a 30% decrease in hospital use by patients with new-onset schizophrenia, risperidone would have to decrease hospital use by 43.2% (i.e. a 13.2% relative advantage) for its societal benefits to justify its increased costs.


Schizophrenia Adis International Limited Clozapine Risperidone Cost Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davies L, Drummond M. The economic burden of schizophrenia. Psychiatric Bull 1990; 14: 522–5CrossRefGoogle Scholar
  2. 2.
    Feinson M, Popper M, Handlesman M. Utilization of public ambulatory mental health services in Israel: a focus on age and gender patterns. Jerusalem: JDC-Brookdale Institute and Ministry of Health, 1992Google Scholar
  3. 3.
    Angrist B, Schulz SC, editors. The neuroleptic-nonresponsive patient: characteristics and treatment. Washington, DC: American Psychiatric Press, 1990: xvii–xxviiiGoogle Scholar
  4. 4.
    Umbrict D, Kane JM. Risperidone: efficacy and safety. Schizophr Bull 1995; 21: 595–606Google Scholar
  5. 5.
    Carpenter WT, Conley RR, Buchanan RW, et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152; 827–32PubMedGoogle Scholar
  6. 6.
    Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994; 55 (9 Suppl. B): 161–5PubMedGoogle Scholar
  7. 7.
    Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45; 789–96PubMedCrossRefGoogle Scholar
  8. 8.
    Pickar D, Owen Jr RR, Litman RE, et al. Predictors of clozapine response in schizophrenia. J Clin Psychiatry 1994; 55 Suppl. B: 129–32PubMedGoogle Scholar
  9. 9.
    Launer M. Personal experience with clozapine. Psychiatric Bull 1991; 15: 223–4CrossRefGoogle Scholar
  10. 10.
    King DJ, Mills PJ. Clozapine: the Holywell experience with the first 24 patients. Ir J Psychol Med 1993; 10: 30–4Google Scholar
  11. 11.
    Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19: 287–302PubMedGoogle Scholar
  12. 12.
    Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant patients I: preliminary report. Psychopharmacology (Berl) 1989; 99 Suppl.: S68–72CrossRefGoogle Scholar
  13. 13.
    Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992; 18: 515–42PubMedGoogle Scholar
  14. 14.
    Zito JM, Volavka J, Craig TJ, et al. Pharmaco-epidemiology of clozapine in 202 inpatients with schizophrenia. Ann Pharmacother 1993; 27: 1262–9PubMedGoogle Scholar
  15. 15.
    Brier A, Buchanan RW, Irish D, et al. Clozapine treatment of outpatients with schizophrenia; outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44: 1145–9Google Scholar
  16. 16.
    Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77: 524–9PubMedCrossRefGoogle Scholar
  17. 17.
    Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160 Suppl. 17; 46–53Google Scholar
  18. 18.
    Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892–7PubMedGoogle Scholar
  19. 19.
    McLarnon MC. Delayed response. In: Yesavage J, editor. Clozapine: a compendium of selected readings. East Hanover (NJ): Sandoz Pharmaceuticals, 1992Google Scholar
  20. 20.
    Conley R, Gounaris C, Tamminga C. Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biol Psychiatry 1994; 35: 746–7CrossRefGoogle Scholar
  21. 21.
    Wilson WH. Clinical review of clozapine treatment in a state hospital. Hosp Community Psychiatry 1992; 43: 700–3PubMedGoogle Scholar
  22. 22.
    Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630–8PubMedGoogle Scholar
  23. 23.
    Reid WH, Mason M, Toprac M. Savings in hospital bed days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261–4PubMedGoogle Scholar
  24. 24.
    Avnon M, Rabinowitz J. Effectiveness of clozapine in hospitalized people with chronic neuroleptic-resistant schizophrenia. Br J Psychiatry 1995; 167: 760–4PubMedCrossRefGoogle Scholar
  25. 25.
    Hirsh SR, Puri R. Clozapine progress in treating refractory schizophrenia. BMJ 1993; 306: 1427–8CrossRefGoogle Scholar
  26. 26.
    Mesotten P, Suy E, Pietquin M, et al. Therapeutic effect and safety of increasing doses of risperidone (R64 766) in psychotic patients. Psychopharmacology (Berl) 1989; 99: 445–9CrossRefGoogle Scholar
  27. 27.
    Castelao JF, Ferreira L, Gelders YG, et al. The efficacy of the D2 and 5-HT2 antagonist risperidone (r64 776) in the treatment of chronic psychosis: an open dose finding study. Schizophr Res 1989; 2: 411–5PubMedCrossRefGoogle Scholar
  28. 28.
    Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Res 1962; 10: 261–76Google Scholar
  29. 29.
    Curtis VA, Kerwin RW. A risk-benefit assessment of risperidone in schizophrenia. Drug Saf 1995; 12 (2): 139–45PubMedCrossRefGoogle Scholar
  30. 30.
    Hoyberg OJ, Fensbo J, Remvig J. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395–402PubMedCrossRefGoogle Scholar
  31. 31.
    Couchinard G, Jones B, Remington G, et al. A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40Google Scholar
  32. 32.
    Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and effect in schizophrenia. Psychopharmacol Bull 1992; 28: 213–8PubMedGoogle Scholar
  33. 33.
    Heinrich K, Kleiser E, Lehmann E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind randomised trial. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 129–37PubMedCrossRefGoogle Scholar
  34. 34.
    Peuskins J. Risperidone in the treatment of chronic schizophrenic patients: an international multi-centre double blind parallel-group comparative study versus haloperidol. Br J Psychiatry 1995; 166: 712–26CrossRefGoogle Scholar
  35. 35.
    Mertens C. Risperidone treatment in psychotic patients: a combined analysis of the data from open long term trials. New Jersey: Jannsen, 1992. Jannsen Clinical Research Report no.: RIS-HOL-9002Google Scholar
  36. 36.
    Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multi centre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295–305PubMedCrossRefGoogle Scholar
  37. 37.
    Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151 (6): 825–35PubMedGoogle Scholar
  38. 38.
    Lindstrom E, Erikkson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402–12PubMedCrossRefGoogle Scholar
  39. 39.
    Marder SR. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. New Jersey: Jannsen, 1991. Jannsen Clinical Research Report no.: RIS-INT-3Google Scholar
  40. 40.
    Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48: 253–73PubMedCrossRefGoogle Scholar
  41. 41.
    Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26PubMedGoogle Scholar
  42. 42.
    Glennie J. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997Google Scholar
  43. 43.
    Van Putten T. Drug refusal in schizophrenia: causes and prescribing hints. Hosp Community Psychiatry 1978; 29: 110–2PubMedGoogle Scholar
  44. 44.
    Kleiser E, Lehmann E, Kinzler E, et al. Randomised double blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15: 45–51CrossRefGoogle Scholar
  45. 45.
    Jones BD, Purdon SE, Labelle A, et al. Risperidone treatment for severe negative symptoms [letter]. Can J Psychiatry 1994; 39: 381PubMedGoogle Scholar
  46. 46.
    Albright PS, Livingstone S, Keegan DL, et al. Reduction of healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin Drug Invest 1996; 5: 289–99Google Scholar
  47. 47.
    Israeli Ministry of Health. Tariff of hospitalization and other services from 1.9.96 [in Hebrew]. Jerusalem: Israeli Ministry of Health, 1996. Report no.: 23/96Google Scholar
  48. 48.
    Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–4PubMedGoogle Scholar
  49. 49.
    Fischer-Cornelssen KA, Ferner UJ. An example of European multi-centre trials: multispectral analysis of clozapine. Psychopharmacol Bull 1976; 12: 34–9PubMedGoogle Scholar
  50. 50.
    Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996; 347: 1024–6PubMedCrossRefGoogle Scholar
  51. 51.
    Mark M, Rabinowitz J, Shemer J. The implementation and technology assessment of clozapine therapy in Israel. In: Shemer J, Schersten T, editors. Technology assessment in health care. Jerusalem: Gefen, 1995Google Scholar
  52. 52.
    Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42PubMedCrossRefGoogle Scholar
  53. 53.
    Rosenheck R, Massari L, Frisman L. Who should receive highcost mental health treatment and for how long? Schizophr Bull 1993; 19 (4): 843–52PubMedGoogle Scholar
  54. 54.
    Craig TJ, Lin SP, El-Defawi MH, at al. Clinical correlates of readmission in a schizophrenic cohort. Psychiatr Q 1985; 57: 5–10PubMedCrossRefGoogle Scholar
  55. 55.
    Lally SJ. ’Does being in here mean there is something wrong with me? ‘Schizophr Bull 1989; 15: 253–65PubMedGoogle Scholar
  56. 56.
    Forrest FM, Forrest IS, Masson AS. Review of rapid urine test for phenothiazine and related drugs. Am J Psychiatry 1961; 118: 300–7PubMedGoogle Scholar
  57. 57.
    Wilson JD, Enoch MD. Estimation of drug rejection by schizophrenic patients, with analysis of clinical factors. Br J Psychiatry 1967; 113: 209–11PubMedCrossRefGoogle Scholar
  58. 58.
    Wilcox DRC, Gillan R, Have EH. Do psychiatric out-patients take their drugs? BMJ 1965; 2: 790–2CrossRefGoogle Scholar
  59. 59.
    Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199–21PubMedCrossRefGoogle Scholar
  60. 60.
    Guest JF, Mart WM, Cookson RF, et al. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996; 10: 59–67Google Scholar
  61. 61.
    Kerwin R, Lofts F. Clozapine in the management of schizophrenia [letter]. BMJ 1993; 307: 199–200PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Department of Medical Technology AssessmentMinistry of HealthJerusalemIsrael
  2. 2.Pharmaceutical DivisionMinistry of HealthJerusalemIsrael
  3. 3.Medical Services DivisionMinistry of HealthJerusalemIsrael

Personalised recommendations